BRISTOL-MYERS SQUIBB COMPANY

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology MATTERS Rank in Class
 
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 1264 6
 
 
C07D HETEROCYCLIC COMPOUNDS 1059 2
 
 
C07K PEPTIDES 256 10
 
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 141 1
 
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 118 60
 
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 101 24
 
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 84 30
 
 
C07C ACYCLIC OR CARBOCYCLIC COMPOUNDS 77 65
 
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 73 33
 
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 73 133
  • No Technologies to Display

Top Patents (by citation)

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2018/0037,921 ANTIBODIES CONJUGATABLE BY TRANSGLUTAMINASE AND CONJUGATES MADE THEREFROM Mar 01, 16 Feb 08, 18 [C12P, A61K, C07K]
2018/0030,057 SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS CGRP RECEPTOR ANTAGONISTS Sep 21, 17 Feb 01, 18 [C07D]
2017/0368,172 USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT Jun 03, 17 Dec 28, 17 [A61K, C07K]
2017/0334,958 PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS AND OTHER BINDING PROTEINS May 01, 17 Nov 23, 17 [C12N, C40B, C12Q, C07K]
2017/0326,249 ANTIBODY-DRUG CONJUGATE OF AN ANTI-GLYPICAN-3 ANTIBODY AND A TUBULYSIN ANALOG, PREPARATION AND USES May 05, 17 Nov 16, 17 [A61K, C07K]
2017/0247,343 THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE Sep 09, 15 Aug 31, 17 [C07D, A61K]
2017/0247,466 TREATMENT OF LUNG CANCER USING AN ANTI-FUCOSYL-GM1 ANTIBODY Sep 24, 15 Aug 31, 17 [A61K, C07K]
2017/0158,776 TREATMENT OF LUNG CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTI-CANCER AGENT May 15, 15 Jun 08, 17 [A61K, C07K]
2017/0121,295 POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF Dec 16, 16 May 04, 17 [C07D]
2017/0107,202 COMPOUNDS USEFUL AS IMMUNOMODULATORS Oct 11, 16 Apr 20, 17 [C07D, C07C, A61K]

View all publication…

  • No Publications to Display

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9918988 Ammonium derivatives for the treatment of hepatitis C Jan 23, 14 Mar 20, 18 [C07D, A61K]
9920031 Indole carboxamide compounds May 30, 17 Mar 20, 18 [A01N, C07D, A61K]
9920034 Crystalline forms of a factor XIa inhibitor Oct 11, 13 Mar 20, 18 [C07D, A61K]
9920036 Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis C Mar 20, 15 Mar 20, 18 [C07D, A61P, A61K]
9920075 Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase Sep 09, 15 Mar 20, 18 [C07D, A61K]
9920108 Targeted therapeutics based on engineered proteins that bind EGFR Nov 30, 15 Mar 20, 18 [A61K, C07K]
9914739 6H-furo[2,3-E]indole compounds for the treatment of hepatitis C Mar 20, 15 Mar 13, 18 [C07D, C07B]
9914740 Tricyclic pyrido-carboxamide derivatives as rock inhibitors Jul 01, 14 Mar 13, 18 [C07D]
9908937 Compositions monovalent for CD28 binding and methods of use Jun 16, 15 Mar 06, 18 [A61K, C07K]
9901572 Aryl dihydropyridinones and piperidinone MGAT2 inhibitors Apr 17, 17 Feb 27, 18 [C07F, C07D, A61K]

View all Patent…

  • No Patents to Display

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2017/0260,232 TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE Abandoned May 23, 17 Sep 14, 17 [A61K, C07K]
2017/0057,961 MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES Abandoned Jan 30, 15 Mar 02, 17 [C07D]
2016/0347,836 TREATMENT OF HODGKIN'S LYMPHOMA USING AN ANTI-PD-1 ANTIBODY Abandoned May 26, 16 Dec 01, 16 [C12Q, A61K, G01N, C07K]
2016/0326,248 ANTI-LAG-3 ANTIBODIES TO TREAT HEMATOLOGICAL MALIGNANCIES Abandoned Jan 26, 15 Nov 10, 16 [C07K]
2016/0318,904 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS Abandoned Jul 08, 16 Nov 03, 16 [C07D]
2016/0304,607 COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTIBODY Abandoned Apr 15, 16 Oct 20, 16 [C07K]
2016/0274,108 DIAGNOSTIC METHODS FOR PAR4 ANTAGONIST THERAPY Abandoned Oct 24, 14 Sep 22, 16 [A61K, G01N]
2016/0222,060 Immunomodulators Abandoned Feb 01, 16 Aug 04, 16 [C07K]
2016/0152,686 FIBRONECTIN BASED SCAFFOLD DOMAINS LINKED TO SERUM ALBUMIN OR MOIETY BINDING THERETO Abandoned Mar 12, 14 Jun 02, 16 [C07K]
2016/0153,990 METHODS FOR IDENTIFYING PATIENTS AT RISK FOR COSTIMULATION BLOCKADE RESISTANT REJECTION Abandoned Mar 27, 14 Jun 02, 16 [G01N]
2016/0038,502 HIV TREATMENT FORMULATION OF ATAZANAVIR AND COBICISTAT Abandoned Oct 06, 14 Feb 11, 16 [A61K]
2016/0024,203 METHODS OF PRODUCING ANTIBODIES IN YEAST Abandoned Mar 14, 14 Jan 28, 16 [C07K]
2016/0024,204 METHODS FOR PRODUCING ANTIBODIES Abandoned Mar 14, 14 Jan 28, 16 [C07K]
2015/0336,975 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION Abandoned Aug 03, 15 Nov 26, 15 [C07D]
2015/0322,119 ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS Abandoned Dec 03, 13 Nov 12, 15 [C07K]
2015/0299,136 LXR MODULATORS Abandoned May 04, 15 Oct 22, 15 [C07D]
2015/0299,804 BIOMARKERS FOR PREDICTING CLINICAL RESPONSE OF CANCER PATIENTS TO TREATMENT WITH IMMUNOTHERAPEUTIC AGENT Abandoned Nov 14, 13 Oct 22, 15 [C12Q, G06F, C07K]
2015/0297,603 HIGH DRUG LOAD TABLET FORMULATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY]-1-METHYLETHYL ESTER Abandoned Jun 30, 15 Oct 22, 15 [A61K]
2015/0290,316 COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT CANCER Abandoned Oct 02, 13 Oct 15, 15 [A61K, C07K]
2015/0252,028 HEPATITIS C VIRUS INHIBITORS Abandoned Oct 24, 12 Sep 10, 15 [C07D, A61K]

View all Patent…

  • No Patents to Display

Top Inventors for This Owner

We are sorry but your current selection exceeds the maximum number of watches () for this membership level. Upgrade to our Level for up to watches!

Owner Watch
BRISTOL-MYERS SQUIBB COMPANY
CANCEL
UPGRADE MEMBERSHIP CANCEL

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to comparisons!

UPGRADE MEMBERSHIP CANCEL

We are sorry but your current selection exceeds the maximum number of portfolios () for this membership level. Upgrade to our Level for up to portfolios!

UPGRADE MEMBERSHIP CANCEL

We are sorry but your current selection exceeds the maximum number of patents allowed in portfolios () for this membership level. Upgrade to our Level for up to patents!

UPGRADE MEMBERSHIP CANCEL